Transgender hormone therapy (male-to-female) medical professional. Inducers of CYP3A4 and other cytochrome P450 enzymes can reduce the effects of MTF HRT. A variety of different sex-hormonal medications are used in feminizing hormone therapy for transgender women. These include estrogens to induce feminization and suppress testosterone levels; antiandrogens such as androgen receptor antagonists, antigonadotropins, GnRH modulators, and 5α-reductase inhibitors to further oppose the effects of androgens like testosterone; and progestogens for various possible though uncertain benefits. Estrogens are the major sex hormones in women, and are responsible for the development and maintenance of feminine secondary sexual characteristics, such as breasts, wide hips, and a feminine
Sexual desire and intimate relationships primary goal of sexual desire. It has also been suggested that women are more likely than men to develop a “relational” or “person-centered” orientation to sexual desire, whereas men are more likely to adopt a “recreational” or “body-centered” orientation to sexuality. These results further support the suggestion that despite generally consistent definitions of sexual desire, perceived differing end goals of sexual desire may exist between the sexes. In keeping with providing definitions of sexual desire consistent with those of theorists, both men and women have consistently expressed their beliefs that the causes of male sexual desire differ from female causes